Targeting menin for precision therapy in high-risk acute myeloid leukemia

被引：0

作者：

Jamil, Abdur ^{[1
]}

Qureshi, Zaheer ^{[2
]}

El-amir, Zain Mary ^{[3
]}

Kupakuwana-Suk, Gillian ^{[4
]}

Akram, Hamzah ^{[5
]}

Ahmad, Mohsin ^{[6
]}

Huselton, Eric ^{[7
]}

机构：

[1] Samaritan Med Ctr, Dept Med, Watertown, NY 13601 USA

[2] Quinnipiac Univ, Frank H Netter MD Sch Med, Bridgeport, CT USA

[3] Univ Michigan, Ann Arbor, MI USA

[4] Univ Ottawa, Ottawa Hosp, Leukemia Fellowship Program, Dept Med,Div Hematol, Ottawa, ON, Canada

[5] Hamilton Hlth Sci, Hamilton, ON, Canada

[6] CHRISTUS Southeast Texas St Elizabeth Hosp, Beaumont, TX USA

[7] Univ Rochester, Dept Hematol Oncol, Rochester, NY USA

来源：

LEUKEMIA RESEARCH REPORTS | 2025年 / 23卷

关键词：

Acute myeloid leukemia; Revumenib; KMT2A; Menin inhibition therapy; INHIBITOR; REVUMENIB;

D O I：

10.1016/j.lrr.2024.100495

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.

引用

页数：4

共 50 条

[1] NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA IN REMISSION
Kadia, T.
Kantarjian, H.
Jabbour, E.
Ravandi, F.
Daver, N.
Cardenas, P.
Brandt, M.
Konopleva, M.
Cortes, J.
HAEMATOLOGICA, 2017, 102 : 54 - 54
[2] Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions
Dhiman, Sandhya
Dhillon, Vikram
Balasubramanian, Suresh Kumar
CANCERS, 2024, 16 (22)
[3] How to manage high-risk acute myeloid leukemia
E H Estey
Leukemia, 2012, 26 : 861 - 869
[4] High-Risk Acute Myeloid Leukemia: A Pediatric Prospective
Cacace, Fabiana
Iula, Rossella
De Novellis, Danilo
Caprioli, Valeria
D'Amico, Maria Rosaria
De Simone, Giuseppina
Cuccurullo, Rosanna
Wierda, William G.
Mahadeo, Kris Michael
Menna, Giuseppe
Tambaro, Francesco Paolo
BIOMEDICINES, 2022, 10 (06)
[5] How to manage high-risk acute myeloid leukemia
Estey, E. H.
LEUKEMIA, 2012, 26 (05) : 861 - 869
[6] Targeted therapies for high-risk acute myeloid leukemia
Perentesis, JP
Sievers, EL
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2001, 15 (04) : 677 - +
[7] Precision therapy for acute myeloid leukemia
Xue Yang
Jianxiang Wang
Journal of Hematology & Oncology, 11
[8] Precision therapy for acute myeloid leukemia
Yang, Xue
Wang, Jianxiang
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[9] Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
Tan, P.
Wei, A.
Mithraprabhu, S.
Cummings, N.
Liu, H. B.
Perugini, M.
Reed, K.
Avery, S.
Patil, S.
Walker, P.
Mollee, P.
Grigg, A.
D'Andrea, R.
Dear, A.
Spencer, A.
BLOOD CANCER JOURNAL, 2014, 4 : e170 - e170
[10] Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
P Tan
A Wei
S Mithraprabhu
N Cummings
H B Liu
M Perugini
K Reed
S Avery
S Patil
P Walker
P Mollee
A Grigg
R D'Andrea
A Dear
A Spencer
Blood Cancer Journal, 2014, 4 : e170 - e170

← 1 2 3 4 5 →